Suppr超能文献

进食障碍的临床精神药理学:研究进展。

Clinical psychopharmacology of eating disorders: a research update.

机构信息

Foundation Chair of Mental Health, School of Medicine, University of Western Sydney and Adjunct Professor of Psychiatry, School of Medicine, James Cook University, Australia.

出版信息

Int J Neuropsychopharmacol. 2012 Mar;15(2):209-22. doi: 10.1017/S1461145711000460. Epub 2011 Mar 25.

Abstract

The paper presents a critical review (with search date 2010) of the major psychotropic medications assessed in eating disorders, namely antipsychotics, antidepressants, mood-stabilizing medications, anxiolytic and other agents. The evidence of efficacy of drug treatments is mostly weak or moderate. In addition, attrition rates are usually higher than for psychotherapies. However, there is support for use of antidepressants, particularly high-dose fluoxetine in bulimia nervosa, and anticonvulsants (topiramate) for binge-eating disorder. Low-dose antipsychotic medication may be clinically useful as adjunct treatment in acute anorexia, particularly where there is high anxiety and obsessive eating-related ruminations and failure to engage, but more trials are needed. Drug therapies such as topiramate and anti-obesity medication may aid weight loss in obese or overweight patients with binge-eating disorder; however, common or potentially serious adverse effects limit their use.

摘要

本文对已评估的治疗进食障碍的主要精神药物(检索日期为 2010 年)进行了批判性回顾,包括抗精神病药、抗抑郁药、心境稳定剂、抗焦虑药和其他药物。药物治疗的疗效证据大多较弱或中等。此外,退出率通常高于心理治疗。然而,抗抑郁药,特别是在神经性贪食症中使用高剂量氟西汀,以及抗惊厥药(托吡酯)治疗暴食障碍,都有一定的支持证据。低剂量抗精神病药物可能在急性厌食症的辅助治疗中有临床应用价值,特别是在焦虑严重、存在强迫性进食相关思考和无法参与治疗的情况下,但需要更多的试验。托吡酯和抗肥胖药物等药物治疗可能有助于减轻暴食障碍肥胖或超重患者的体重;然而,常见或潜在的严重不良反应限制了它们的使用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验